Wakisaka T, Sou S
Dept. of Obstetrics and Gynecology, Sendai Shakaihoken Hospital.
Gan To Kagaku Ryoho. 1988 May;15(5):1795-8.
A 49-year-old woman with recurrent ovarian cancer clear cell carcinoma was treated by etoposide. The recurrence was found seven months after second operation. The etoposide (50 mg/day per os) was first given for 2 weeks and then etoposide (25 mg/day per os) for 4.5 months. After one month of treatment the target tumor mass was reduced in size, and the therapy was continued for 4 months in our Outpatient Department. A partial response was confirmed by B-Scope, and the tumor marker CA-125 was reduced to 15 U/ml from 210 U/ml before treatment. No side effects were observed in the patient. This case suggests that etoposide might be effective for recurrent ovarian cancer and the whole treatment course could be handled in the Outpatient Department.